Display options
Cite
Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells. 2010;2(1):5-12doi: 10.4252/wjsc.v2.i1.5.
Galderisi, U., Giordano, A., & Paggi, M. G. (2010). The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World journal of stem cells, 2(1), 5-12. https://doi.org/10.4252/wjsc.v2.i1.5
Galderisi, Umberto, et al. "The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents." World journal of stem cells vol. 2,1 (2010): 5-12. doi: https://doi.org/10.4252/wjsc.v2.i1.5
Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells. 2010 Feb 26;2(1):5-12. doi: 10.4252/wjsc.v2.i1.5. PMID: 21607110; PMCID: PMC3097917.
Copy Download .nbib Format: NLM
Share it on

World J Stem Cells. 2010 Feb 26;2(1):5-12. doi: 10.4252/wjsc.v2.i1.5.

The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents.

World journal of stem cells

Umberto Galderisi, Antonio Giordano, Marco G Paggi

Affiliations

  1. Umberto Galderisi, Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, PA 19122, United States.

PMID: 21607110 PMCID: PMC3097917 DOI: 10.4252/wjsc.v2.i1.5

Abstract

In cancer biology, mesenchymal stem cells (MSCs) display aspects that can appear contradictory. On one hand, these cells possess several features which give them the ability to specifically target and then sustain cancer cells in their ability to survive the multifaceted host response against cancer. On the other hand, due to this excellent aptitude to home-in on tumor tissues, regardless their location in the host's body, MSCs are considered to be extremely selective vehicles to reach cancer cells specifically. Recently, MSC sustainment of cancer cell growth is a hot research topic. Indeed, these cells are known to sustain tumor angiogenesis and metastasis formation, to create a microenvironment favorable for cancer cell growth and to down-modulate the immune system capabilities in the host organism. On the other hand, since scientists became able to take advantage of their extremely selective capability to target cancer cells, MSCs are now also thought of in a different light. Indeed, MSCs are now considered a promising vehicle for local expression or delivery of even particularly toxic anticancer agents, ranging from Herpes Simplex Virus to locally-acting antineoplastic drugs. On this basis, investigation is now focused on how to impair the pro-neoplastic features of MSCs on one hand whilst taking advantage of their specific tropism toward cancer cells, on the other. As with the two faces of Janus, this review will concisely explore the research activity in these two apparently conflicting fields.

Keywords: Angiogenesis; Cancer; Cell therapy; Immunomodulation; Mesenchymal stem cells; Niche

References

  1. J Thromb Haemost. 2007 Apr;5(4):826-34 - PubMed
  2. Cancer Res. 2004 Dec 1;64(23):8492-5 - PubMed
  3. Ageing Res Rev. 2006 Feb;5(1):91-116 - PubMed
  4. Leukemia. 2007 Feb;21(2):304-10 - PubMed
  5. Nature. 2007 Oct 4;449(7162):557-63 - PubMed
  6. Stem Cells. 1995 Sep;13(5):477-86 - PubMed
  7. Cancer Res. 2007 Jul 1;67(13):6304-13 - PubMed
  8. Gene Ther. 2003 Apr;10(8):621-9 - PubMed
  9. Blood. 2001 Nov 1;98(9):2615-25 - PubMed
  10. Blood. 2003 Nov 15;102(10):3837-44 - PubMed
  11. Cancer Res. 2009 Jun 1;69(11):4791-9 - PubMed
  12. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2397-402 - PubMed
  13. Circ Res. 2004 Mar 19;94(5):678-85 - PubMed
  14. Mol Cancer Ther. 2006 Mar;5(3):755-66 - PubMed
  15. J Cell Biochem. 2004 Apr 15;91(6):1146-58 - PubMed
  16. Nature. 2003 Oct 23;425(6960):841-6 - PubMed
  17. Cancer Res. 2007 Nov 15;67(22):10889-98 - PubMed
  18. Breast Cancer Res Treat. 2007 Oct;105(2):157-67 - PubMed
  19. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7 - PubMed
  20. Oncogene. 2004 Jun 24;23(29):5092-4 - PubMed
  21. J Cell Sci. 2004 Jun 15;117(Pt 14):2971-81 - PubMed
  22. Stem Cells. 2004;22(3):377-84 - PubMed
  23. Cell Death Differ. 2005 Jan;12(1):65-77 - PubMed
  24. Science. 1997 Apr 4;276(5309):71-4 - PubMed
  25. Cancer Res. 2005 Apr 15;65(8):3035-9 - PubMed
  26. Nat Med. 2003 Sep;9(9):1158-65 - PubMed
  27. Tissue Eng. 2005 May-Jun;11(5-6):896-903 - PubMed
  28. J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603 - PubMed
  29. Exp Hematol. 2000 Aug;28(8):875-84 - PubMed
  30. Handb Exp Pharmacol. 2007;(180):263-83 - PubMed
  31. Int J Cardiol. 2005 Dec 7;105(3):274-82 - PubMed
  32. Nature. 2003 Oct 23;425(6960):836-41 - PubMed
  33. Circulation. 2005 Jan 18;111(2):150-6 - PubMed
  34. Stem Cells. 2001;19(3):180-92 - PubMed
  35. Cancer Res. 2005 Apr 15;65(8):3307-18 - PubMed
  36. J Cell Mol Med. 2011 Feb;15(2):433-44 - PubMed
  37. Exp Hematol. 2005 Sep;33(9):965-70 - PubMed
  38. Cancer Res. 2002 Jul 1;62(13):3603-8 - PubMed
  39. Exp Dermatol. 2006 Nov;15(11):865-74 - PubMed
  40. Clin Cancer Res. 2007 Sep 1;13(17):5020-7 - PubMed
  41. J Immunol. 2007 Aug 1;179(3):1595-604 - PubMed
  42. Science. 1999 Apr 2;284(5411):143-7 - PubMed
  43. Oncogene. 2004 Jun 24;23(29):5095-8 - PubMed
  44. J Clin Invest. 2000 Jun;105(12):1663-8 - PubMed
  45. Blood. 2006 Nov 15;108(10):3245-52 - PubMed
  46. Handb Exp Pharmacol. 2006;(174):249-82 - PubMed
  47. Stem Cells. 2007 Jul;25(7):1761-8 - PubMed
  48. Stem Cells. 2006 Apr;24(4):1030-41 - PubMed
  49. Int J Cancer. 2005 Jul 20;115(6):885-92 - PubMed
  50. J Gene Med. 2009 May;11(5):373-81 - PubMed

Publication Types